Drugs / DCTY1102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07014878 | May 2026 → Aug 2028 expected | colorectal cancer, lung cancer, malignant pancreatic neoplasm | Beijing DCTY Biotech Co.,Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCTY1102 | “DCTY1102 Injection is an autologous genetically modified T-cell receptor (TCR) T-cell therapy product targeting the KRAS/NRAS G12D mutant neoantigen presented in the context of...” NCT07014878 ↗ |
| Known as | DCTY1102 Injection | “DCTY1102 Injection is an autologous genetically modified T-cell receptor (TCR) T-cell therapy product targeting the KRAS/NRAS G12D mutant neoantigen presented in the context of...” NCT07014878 ↗ |
| Modality | Cell therapy | “DCTY1102 Injection is an autologous genetically modified T-cell receptor (TCR) T-cell therapy product” NCT07014878 ↗ |
| Route | Intravenous | “single intravenous infusion of DCTY1102” NCT07014878 ↗ |
| Target | KRAS | “targeting the KRAS/NRAS G12D mutant neoantigen presented in the context of HLA-A11:01.” NCT07014878 ↗ |
| Target | NRAS | “targeting the KRAS/NRAS G12D mutant neoantigen presented in the context of HLA-A11:01.” NCT07014878 ↗ |